<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The identification of MHC-restricted and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>-specific cytotoxic T lymphocytes (CTLs) provides strong evidence in support of T cell-mediated immune surveillance against human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells </plain></SENT>
<SENT sid="1" pm="."><plain>These CTLs recognize short <z:chebi fb="7" ids="16670">peptides</z:chebi> derived from <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>-associated antigens in conjunction with class I molecules expressed on <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells </plain></SENT>
<SENT sid="2" pm="."><plain>In contrast to these observations there are now numerous examples to suggest that a number of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> escape this CTL-mediated control either by down-regulating accessory molecules or by blocking the intracellular processing of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>-specific antigens </plain></SENT>
<SENT sid="3" pm="."><plain>Recently a number of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cell lines have been identified which display a transcriptional deficiency of transporters associated with antigen processing (also referred to as TAP) </plain></SENT>
<SENT sid="4" pm="."><plain>The Epstein-Barr virus (EBV)-associated <z:e sem="disease" ids="C0006413" disease_type="Neoplastic Process" abbrv="BL">tumour, Burkitt's</z:e> <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>), is a classic example in this category </plain></SENT>
<SENT sid="5" pm="."><plain>In the present study we have restored class I-restricted antigen processing in a <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell line by transfecting a minigene expression vector encoding a CTL <z:chebi fb="0" ids="53000">epitope</z:chebi> derived from EBV linked to an endoplasmic reticulum translocation signal sequence </plain></SENT>
<SENT sid="6" pm="."><plain>These minigene transfected <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells were not only susceptible to lysis by virus-specific CTL but were also capable of efficiently activating an antigen-specific CTL response </plain></SENT>
<SENT sid="7" pm="."><plain>Interestingly, the immunogenicity of these <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells was not affected by the significantly down-regulated expression of <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecules such as LFA1 alpha, LFA1 beta and LFA3 </plain></SENT>
<SENT sid="8" pm="."><plain>These findings suggest that resistance of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells to CTL-mediated immune control can be reversed if the relevant <z:chebi fb="7" ids="16670">peptide</z:chebi> <z:chebi fb="0" ids="53000">epitopes</z:chebi> are appropriately presented on the cell surface </plain></SENT>
</text></document>